Loading organizations...
INNOVENTRIC, based in Rehovot, Israel, develops transcatheter solutions for treating tricuspid regurgitation (TR) and right heart disease using its Trillium™ technology. The company's device utilizes a heterotopic, cross-caval approach, anchoring a prosthetic valve to the vena cava to replace native valve function, targeting the $10 billion transcatheter heart valve market. To date, INNOVENTRIC has raised $45.39 million in total funding, including a $28.5 million Series B round led by RA Capital Management. The Trillium™ technology has undergone over 10 implantations in European first-in-human trials, with additional investment from the European Investment Committee (EIC). Founded in 2017 by Amir Danino, Rafi Benary, and David Planer, the company is led by CEO Danino. Its business model centers on venture capital-funded medical device startup through equity financing rounds.
INNOVENTRIC has raised $29.0M across 1 funding round.
INNOVENTRIC has raised $29.0M in total across 1 funding round.
INNOVENTRIC has raised $29.0M across 1 funding round. Most recently, it raised $29.0M Series B in October 2024.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Oct 1, 2024 | $29M Series B | — | Endeavor Venture Funds, RA Capital | Announced |
INNOVENTRIC has raised $29.0M in total across 1 funding round.
INNOVENTRIC's investors include Endeavor Venture Funds, RA Capital.
Innoventric is an Israeli medical device startup based in Ness-Ziona, specializing in structural heart solutions for tricuspid regurgitation (TR), a condition affecting patients with structural heart disease.[1][2][3][4] The company develops transcatheter, cross-caval technologies like Trillium™, Koala™, and Unica™, which provide anatomy-agnostic treatments to expand care beyond traditional patients to overlooked populations with complex anatomies.[1][2][5] These percutaneous heterotopic devices simplify TR procedures, improve accessibility, and aim for better health outcomes through data-driven innovation and a robust patent portfolio.[1][5]
Serving physicians and TR patients globally, Innoventric addresses the unmet need for effective, simple interventions in a market where many cases remain untreated due to anatomical challenges.[2] Growth momentum includes a $14M Series A round led by a US investor, a €2.5M Horizon Europe grant (top 1.5% of 4,000+ applicants), successful First-In-Human (FIH) trials in Europe, compassionate use cases in the EU, Canada, and US Early Feasibility Study (EFS) for Trillium™.[2][5]
Founded by Amir Danino (CEO), Innoventric emerged from expertise in cardiovascular devices and entrepreneurial ventures in heart failure treatments.[1][2] Danino previously served as medical director for V-Wave (inter-atrial shunt for heart failure) and co-founded companies like Hilbert Paradox (digital health data, acquired by a CRO), Ainthoven (cardiac signal analytics), and Amynas (nanofiber tech for implants).[1] The idea stemmed from clinical gaps in TR management, focusing on cross-caval approaches to bypass anatomical limitations in tricuspid valve repair.[1][3]
Early traction built on rigorous clinical research, leading to a strong patent portfolio and pivotal milestones like the Horizon Europe grant and Series A funding, validating their data-driven path from concept to human trials.[1][2][5]
Innoventric rides the structural heart revolution, particularly the surge in transcatheter therapies for right-heart conditions like TR, where prevalence is rising with aging populations and heart failure comorbidities.[1][2] Timing aligns with post-TAVR (transcatheter aortic valve replacement) momentum, as TR affects up to 65% of heart failure patients, yet treatments lag due to anatomical complexity—Innoventric's cross-caval sinuation overcomes this.[3][5]
Market forces favor them: EU/US regulatory progress (Horizon grants, EFS), investor interest ($14M A-round), and a €2.5B+ global structural heart market growing 15%+ annually.[2] They influence the ecosystem by pioneering heterotopic solutions, potentially standardizing TR care and enabling future valve-in-valve procedures, broadening medtech accessibility.[1][5]
Innoventric is poised for pivotal trials and regulatory milestones, with Trillium™ advancing in US EFS and EU compassionate data supporting CE Mark/CE approval pathways.[5] Trends like AI-enhanced imaging, personalized devices, and right-heart focus will accelerate adoption, especially as TR awareness grows via guidelines updates.[1][2]
Their influence may evolve from niche innovator to category leader, scaling via partnerships and global expansion, ultimately simplifying TR care as TAVR did for aortic disease—cementing cross-caval as a cornerstone for underserved heart patients.[2][5]
